Zentalis Pharmaceuticals to Participate in the Oppenheimer Healthcare Life Sciences Conference
13 February 2024 - 11:00PM
Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage
biopharmaceutical company discovering and developing clinically
differentiated small molecule therapeutics targeting fundamental
biological pathways of cancer, today announced that Kimberly
Blackwell, M.D., Chief Executive Officer of Zentalis, will
participate in a webcast fireside chat at the Oppenheimer
Healthcare Life Sciences Conference on Wednesday, February 14, 2024
at 12:40 p.m. ET.
Access to a live webcast of this event, as well as an archived
recording, will be available under the “Events & Presentations”
tab on the Investors & Media section of the Company’s
website.
About Zentalis Pharmaceuticals
Zentalis® Pharmaceuticals, Inc. is a clinical-stage
biopharmaceutical company discovering and developing clinically
differentiated small molecule therapeutics targeting fundamental
biological pathways of cancers. The Company’s lead product
candidate, azenosertib (ZN-c3), is a potentially first-in-class and
best-in-class WEE1 inhibitor for advanced solid tumors and
hematologic malignancies. Azenosertib is being evaluated as a
monotherapy and in combination across multiple clinical trials and
has broad franchise potential. In clinical trials, azenosertib has
been well tolerated and has demonstrated anti-tumor activity as a
single agent across multiple tumor types and in combination with
several chemotherapy backbones. As part of its azenosertib clinical
development program, the Company is exploring enrichment strategies
targeting tumors of high genomic instability, such as Cyclin E1
positive tumors and homologous recombination deficient tumors. The
Company is also leveraging its extensive experience and
capabilities across cancer biology and medicinal chemistry to
advance its research on protein degraders. Zentalis has operations
in both New York and San Diego.
For more information, please visit www.zentalis.com. Follow
Zentalis on Twitter at @ZentalisP and on LinkedIn at
www.linkedin.com/company/zentalis-pharmaceuticals.
Contact:
Carlo Tanzi, Ph.D.Kendall Investor
Relationsctanzi@kendallir.com
Zentalis Pharmaceuticals (NASDAQ:ZNTL)
Historical Stock Chart
From Apr 2024 to May 2024
Zentalis Pharmaceuticals (NASDAQ:ZNTL)
Historical Stock Chart
From May 2023 to May 2024